Pelosi plan to lower drug prices faces political challenges

Amy Baxter | | Health Exec | Policy & Regulations

House Speaker Nancy Pelosi’s (D-CA) bill to lower drug prices is facing new challenges as congressional Democrats debate changes to the plan, The Hill reported.

Centrist Democrats are warning leadership that if the plan moves further to the left, it could start to lose support and votes. Others are pushing for stronger reforms to “toughen up” the legislation.

“Pelosi will have to thread the needle between these dueling factions as she plans to bring the measure to the floor as soon as mid-November,” the report reads.

Pelosi introduced the plan in September, calling the bill The Lower Drug Costs Now Act. The plan enables the HHS to negotiate lower prices for hundreds of Medicare drugs––something currently prohibited under law.

See the full story below:

House Democrats clash over Pelosi's drug pricing bill

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

FDA issues Class I alert on Philips ventilators after 4 injuries
Trump selects Emmy-winning TV personality Dr. Oz to head CMS
FDA issues Class I recall of infusion pump batteries due to risk of burns
When life sciences met artificial intelligence
DEA, HHS extend telehealth controlled substance prescription rule
Public health contrarian RFK Jr. nominated to HHS secretary

Around the web

Cardiovascular Business
Payment cuts and beyond: Key takeaways for cardiologists from the 2025 Medicare Physician Fee Schedule

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

AI in Healthcare
A modest proposal to rally AI regulators around a simple game plan

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”

Cardiovascular Business
FDA commissioner urges clinicians to join fight against medical misinformation

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

Design by Adaptive Theme
Trimed Popup
Trimed Popup